The Immune Escape Signature Predicts the Prognosis and Immunotherapy Sensitivity for Pancreatic Ductal Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Sep 23

PMID 36147906

Authors

Hao Lu

Li-Yan Zheng

Ling-Yan Wu

Jun Chen

Na Xu

Sui-Cai Mi

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies worldwide. Immune escape is considered to be a reason for immunotherapy failure in PDAC. In this study, we explored the correlation between immune escape-related genes and the prognosis of PDAC patients.

Methods: 1163 PDAC patients from four public databases, including The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), Array-express, and Gene Expression Omnibus (GEO), were included in our study. Cox regression analysis was used to identify the 182 immune genes which were significantly associated with overall survival (OS). And then we established an immune escape-related gene prognosis index (IEGPI) score using several datasets as the training cohort and validated it using the validation cohort. Kaplan-Meier (KM) and Cox regression analysis were used to detect the relationship of IEGPI score with OS. We further explored the relationship between the IEGPI and immune indexes. And the prediction value of response for immunotherapy in Tumor Immune Dysfunction and Exclusion (TIDE) dataset.

Results: We establish an IEGPI score based on 27 immune escape genes which were significantly related to the prognosis of OS in PDAC patients. Patients in the high-IEGPI group had a significantly worse overall survival rate compared with that in the low-IEGPI groups by KM curves and cox-regression. 5 of the 32 cancer types in TCGA could be significantly distinguished in survival rates through the low- and high-IEGPI groups. Moreover, the correlation between the IEGPI score was negatively correlated with an immune score in several datasets. And higher IEGPI better recurrence-free survival (RFS) and OS in the patients after patients were treated with both PD-1 and CTLA4 in the public datasets (P<0.05). Intriguingly, by using RT-PCR, we verified that the gene of PTPN2, CEP55, and JAK2 were all higher in the BxPC-3 and PANC-1 than HPDE5 cells. Lastly, we found that the IEGPI score was higher in K-rasLSL.G12D/+, p53LSL.R172H/+, Pdx1Cre (KPC) mice model with anti-PD-L1 than that without anti-PD-L1.

Conclusion: Using the immune escape-related genes, our study established and validated an IEGPI score in PDAC patients from the public dataset. IEGPI score has the potential to serve as a prognostic marker and as a tool for selecting tumor patients suitable for immunotherapy in clinical practice.

Citing Articles

Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer.

Mantini G, Agostini A, Tufo M, Rossi S, Kulesko M, Carbone C Sci Rep. 2024; 14(1):31749.

PMID: 39738404 PMC: 11685961. DOI: 10.1038/s41598-024-82563-9.

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.

Mikolajewicz N, Tatari N, Wei J, Savage N, Farias A, Dimitrov V Acta Neuropathol. 2024; 148(1):74.

PMID: 39592459 PMC: 11599368. DOI: 10.1007/s00401-024-02831-w.

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.

Li H, Wang S, Yang Z, Meng X, Niu M Bioact Mater. 2024; 36:376-412.

PMID: 38544737 PMC: 10965438. DOI: 10.1016/j.bioactmat.2024.03.003.

miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.

Pengjie Y, Rong J, Pengfei N Sci Rep. 2024; 14(1):305.

PMID: 38172247 PMC: 10764758. DOI: 10.1038/s41598-023-50938-z.

References

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

Birnbaum D, Bertucci F, Finetti P, Birnbaum D, Mamessier E . Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2018; 1869(2):248-255. DOI: 10.1016/j.bbcan.2018.02.001. View

Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View

Zhang X, Chen Q, Liu Q, Wang Y, Wang F, Zhao Z . Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2021; 25(12):5615-5627. PMC: 8184720. DOI: 10.1111/jcmm.16573. View

Wang X, Li X, Wei X, Jiang H, Lan C, Yang S . PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther. 2020; 5(1):38. PMC: 7162990. DOI: 10.1038/s41392-020-0144-8. View

Zhang H, Liu C, Kong Y, Huang H, Wang C, Zhang H . TGFβ signaling in pancreatic ductal adenocarcinoma. Tumour Biol. 2014; 36(3):1613-8. DOI: 10.1007/s13277-014-2757-4. View

Crawford H, Scoggins C, Washington M, Matrisian L, Leach S . Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest. 2002; 109(11):1437-44. PMC: 150998. DOI: 10.1172/JCI15051. View

Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S . Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020; 581(7806):100-105. PMC: 7296553. DOI: 10.1038/s41586-020-2229-5. View

Liang C, Shi S, Qin Y, Meng Q, Hua J, Hu Q . Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut. 2019; 69(5):888-900. DOI: 10.1136/gutjnl-2018-317163. View

10.

Farren M, Mace T, Geyer S, Mikhail S, Wu C, Ciombor K . Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016; 22(10):2565-74. PMC: 4867263. DOI: 10.1158/1078-0432.CCR-15-1732. View

11.

Merika E, Syrigos K, Saif M . Desmoplasia in pancreatic cancer. Can we fight it?. Gastroenterol Res Pract. 2012; 2012:781765. PMC: 3485537. DOI: 10.1155/2012/781765. View

12.

Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T . Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019; 10:496. PMC: 6465515. DOI: 10.3389/fimmu.2019.00496. View

13.

Witkiewicz A, Williams T, Cozzitorto J, Durkan B, Showalter S, Yeo C . Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008; 206(5):849-54. DOI: 10.1016/j.jamcollsurg.2007.12.014. View

14.

Minicozzi P, Cassetti T, Vener C, Sant M . Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol. 2018; 55:52-60. DOI: 10.1016/j.canep.2018.04.011. View

15.

Wang H, Gao Y, Vafaei S, Yu Q, Zhang J, Wang L . A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy. Mol Ther Nucleic Acids. 2022; 27:427-438. PMC: 8733234. DOI: 10.1016/j.omtn.2021.12.015. View

16.

Giulietti M, Occhipinti G, Principato G, Piva F . Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol (Dordr). 2016; 39(4):379-88. DOI: 10.1007/s13402-016-0283-7. View

17.

Morrison A, Byrne K, Vonderheide R . Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018; 4(6):418-428. PMC: 6028935. DOI: 10.1016/j.trecan.2018.04.001. View

18.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

19.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

20.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View